基于细胞的疗法治疗急性呼吸窘迫综合征:现状与展望
间充质基质细胞(MSC)通过调节炎症、降低肺通透性和促进修复对急性呼吸窘迫综合征(ARDS)发挥潜在治疗作用。临床研究显示MSC安全耐受,在特定临床场景有 promising 获益,部分国家已批准其用于特定适应症。本文结合COVID-19和经典ARDS的近期细胞治疗试验及移植物抗宿主病研究,重新评估MSC治疗ARDS的前景,指出未知问题与转化挑战并提出评估路径。
要点
- MSC通过调节中性粒细胞、巨噬细胞和T细胞功能,减轻炎症、肺水肿并促进修复。
- 临床研究提示MSC安全耐受,在特定临床场景有 promising 治疗获益。
- 需结合近期COVID-19和经典ARDS试验重新评估MSC对ARDS的治疗潜力。
核心结论
- MSC疗法对ARDS具有治疗潜力,但需结合近期试验证据重新评估其临床转化前景。
主要发现
- MSC通过调节中性粒细胞、巨噬细胞和T细胞功能减轻过度炎症,降低肺通透性和肺水肿,促进组织修复。
- 临床研究表明MSC安全且耐受良好,在特定临床场景显示出 promising 治疗获益。
- 部分国家已批准MSC用于特定适应症,移植物抗宿主病是少数获批适应症之一。
局限性
- 当前文献存在重要未知问题,临床转化面临挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is considerable interest in the potential for cell-based therapies, particularly mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory distress syndrome (ARDS). MSCs exert effects via diverse mechanisms including reducing excessive inflammation by modulating neutrophil, macrophage and T-cell function, decreasing pulmonary permeability and lung edema, and promoting tissue repair. Clinical studies indicate that MSCs are safe and well tolerated, with promising therapeutic benefits in specific clinical settings, leading to regulatory approvals of MSCs for specific indications in some countries.This perspective reassesses the therapeutic potential of MSC-based therapies for ARDS given insights from recent cell therapy trials in both COVID-19 and in 'classic' ARDS, and discusses studies in graft-vs.-host disease, one of the few licensed indications for MSC therapies. We identify important unknowns in the current literature, address challenges to clinical translation, and propose an approach to facilitate assessment of the therapeutic promise of MSC-based therapies for ARDS.
引用
- Curley GF, O'Kane CM, McAuley DF, et al. Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now? Am J Respir Crit Care Med. 2024. PMID: 38324017. doi:10.1164/rccm.202311-2046CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。